Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialResearch in context

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialResearch in context

Summary: Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome. Later, meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan....

Full description

Bibliographic Details
Main Authors: John R. Jones, David A. Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Molly Reed, Mark T. Drayson, Roger G. Owen, Kevin D. Boyd, Gordon Cook, Gareth J. Morgan, Graham H. Jackson
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:EClinicalMedicine
Subjects:
Myeloma
Lenalidomide
Lenalidomide maintenance
Second primary malignancy
SPM
Transplant eligible
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023002766

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023002766

Similar Items